Answers are grounded in this paper and cite their sources.
Protocol demonstrates effective NK cell expansion and cytotoxic activity in pediatric leukemia treatment.
for NK lymphocyte-enriched biomedical cell product is a pressing issue in clinical biotechnology. Based on numerous scientificand clinical studies, we have settled on the NK lymphocyte expansion protocol with a modified feeder line K562 and peripheralblood mononuclear cells as a starting fraction, not including CD3+ lymphocyte depletion step. In this paper, we present theresults of a validation process of NK lymphocyte-enriched biomedical cell product manufacturing. The study was approvedby the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center ofPediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The resulting cell productsmet all stated quality control criteria, contained a high percentage of NK cells, and demonstrated strong cytotoxic activityagainst the THP-1 and Jeko-I cell lines. Expansion folds allowed us to achieve the desired clinical dosage in all processes. Thesurface marker expression profile of the expanded NK cells corresponded to an activated and highly proliferative phenotype.The residual lymphocytes were represented mainly by T cells with an effector phenotype, and a significant decrease in TCRabpercentage was observed compared to the initial fraction. These data provide the basis for a clinical study of the feasibility andsafety of the infusions of the cellular products produced according to this protocol for pediatric refractory leukemia treatment.
No takes yet. Share an insight, caveat, or question.
Kulakovskaya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: